Noureddin M, Frias JP, Neff GW, Lucas KJ, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 2025;406:719-730.
PMID: 40818852